Start Your Search
Best abstracts selected from submissions 2 (ID 2)
- Event: ACLC 2018
- Type: Oral Session
- Presentations: 1
- Coordinates: 11/08/2018, 16:20 - 17:00, Jade Ballroom
OA03 - Afatinib Followed by Osimertinib in Real-World Patients with EGFR Mutation-Positive Advanced NSCLC: The Giotag Study (ID 106)
16:20 - 17:00 | Author(s): A. M
Afatinib has demonstrated efficacy in EGFR mutation-positive (EGFRm+) NSCLC; however, resistance develops over time, most commonly due to the emergence of the T790M mutation. Osimertinib has shown clinical activity in the treatment of T790M-positive disease following progression on a first-line tyrosine kinase inhibitor. Further information on outcomes of sequencing options is necessary to optimize treatment outcomes for patients.
This observational study is the first to evaluate outcomes of real-world patients who sequentially received first-line afatinib followed by osimertinib. Data were retrospectively collected between December 2017 and May 2018. Patients had common EGFRm+ (Del19, L858R) advanced NSCLC and acquired T790M after first-line afatinib. Patients must have completed afatinib treatment and started osimertinib treatment ?10 months prior to data entry. Patients with active brain metastases were excluded. The primary outcome was time on treatment (ToT) from initiation of afatinib until discontinuation of osimertinib.
A total of 204 patients were included in the study; of these, 24.5/67.6% were Asian and non-Asian (Caucasian and African American), 15.3% had ECOG performance status ?2, and 73.5/26.0% were Del19/L858R-positive. Overall median ToT was 27.6 months (90% CI: 25.9